MIR564

Summary

MIR564 (microRNA 564, HGNC:32820) is a microRNA gene on chromosome 3p21.31.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 693149 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32820
Approved symbol	MIR564
Name	microRNA 564
Location	3p21.31
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-564
Ensembl gene	ENSG00000284498
Ensembl biotype	miRNA
Entrez	693149
RNAcentral	URS000075A5C3 — miRNA, 94 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000385049

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000385049 — 1 exons

Exon	Start	End
ENSE00001500056	44861888	44861981

Expression profiles

Bgee: expression breadth broad, 81 present calls, max score 91.01.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1619 / max 15.2469, expressed in 49 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
36350	18.0086	1744
36349	0.1619	49

Top tissues by expression

81 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	91.01	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	78.28	gold quality
monocyte	CL:0000576	77.86	gold quality
skeletal muscle tissue	UBERON:0001134	74.09	gold quality
liver	UBERON:0002107	73.84	gold quality
muscle of leg	UBERON:0001383	72.83	gold quality
gastrocnemius	UBERON:0001388	72.42	gold quality
left adrenal gland cortex	UBERON:0035825	72.19	gold quality
blood	UBERON:0000178	72.13	gold quality
adult mammalian kidney	UBERON:0000082	71.83	gold quality
heart left ventricle	UBERON:0002084	71.50	gold quality
left adrenal gland	UBERON:0001234	71.35	gold quality
heart	UBERON:0000948	70.74	gold quality
prefrontal cortex	UBERON:0000451	70.64	gold quality
right atrium auricular region	UBERON:0006631	70.46	gold quality
stomach	UBERON:0000945	70.07	gold quality
substantia nigra	UBERON:0002038	70.03	gold quality
body of stomach	UBERON:0001161	69.19	gold quality
caudate nucleus	UBERON:0001873	69.12	gold quality
lower esophagus muscularis layer	UBERON:0035833	68.99	gold quality
right adrenal gland cortex	UBERON:0035827	68.69	gold quality
granulocyte	CL:0000094	68.66	gold quality
Ammon’s horn	UBERON:0001954	68.60	gold quality
endometrium	UBERON:0001295	68.54	gold quality
Brodmann (1909) area 9	UBERON:0013540	68.42	gold quality
body of pancreas	UBERON:0001150	68.39	gold quality
right lobe of liver	UBERON:0001114	68.28	gold quality
nucleus accumbens	UBERON:0001882	68.21	gold quality
left coronary artery	UBERON:0001626	67.89	gold quality
urinary bladder	UBERON:0001255	67.85	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 9)

• Deregulation of miR-31, miR-155, and miR-564 has a role in chronic myeloid leukemia (CML). (PMID:22511990)
• study revealed the tumor suppressor role of miR-564, indicating restoration of miR-564 as a potential therapeutic strategy for the treatment of lung cancer. (PMID:26498524)
• miR-564 is a potential dual inhibitor of PI3K and MAPK pathways, and may be an attractive target and prognostic marker for breast cancer. (PMID:27600857)
• Up-regulated mir-564 promoted the development of hypertrophic scar via enhancing the expression of TGF-beta1 (PMID:28933518)
• Study demonstrated that miR-564 was down-regulated in osteosarcoma (OS) tissues and cell lines. Overexpression of miR-564 inhibited the growth and glucose metabolism of OS cells by targeting Akt. (PMID:29248580)
• data for the first time suggest that downregulated miR-564 may be used as a novel prognosis predictor of osteosarcoma. (PMID:30280765)
• Knockdown of circ_0003340 induces cell apoptosis, inhibits invasion and proliferation through miR-564/TPX2 in esophageal cancer cells. (PMID:32535036)
• TMEM63C, a Potential Novel Target for Albuminuria Development, Is Regulated by MicroRNA-564 and Transforming Growth Factor beta in Human Renal Cells. (PMID:33080601)
• Epigenetic silencing of miR564 contributes to the leukemogenesis of t(8;21) acute myeloid leukemia. (PMID:33201243)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.